Developing an UPLC-MSMS Method to Quantify a Novel Anticancer Chalcone BOC26P for Its Pharmacokinetic Study In vivo

Simple item page
dc.contributor.authorLin, Linaen_US
dc.contributor.authorChen, Lexingen_US
dc.contributor.authorXu, Junen_US
dc.contributor.authorCai, Shaohuien_US
dc.contributor.authorLu, Danyien_US
dc.date.accessioned2020-11-18T10:29:12Z
dc.date.available2020-11-18T10:29:12Z
dc.date.issued2019-08
dc.description.abstractObjective BOC26P is a potent anticancer candidate which inhibits microtubule polymerization and shows strongcytotoxic activity against numerous cancer cell lines and drug resistant cell lines. To support the pharmacokineticstudy of BOC26P, a rapid, selective and reproducible UPLC-MS/MS method was developed.Method Dexamethasone sodium phosphate (DSP) was used as an internal standard (IS). Following proteinprecipitation by using methanol-acetonitrile solution (1:1, v/v) with an internal standard DSP, the processedsamples were chromatographed on an UPLC X Bridge 71 TM C8 column (4.6 mm × 100 mm, 3.5 μm) with a mobilephase that consisted of acetonitrile and 2mmol/L ammonium acetate aqueous solution (containing 0.25%ammonia) with a gradient elution pumped at a flow rate of 0.4 mL/min. Mass spectrometric detection wasperformed in the positive electrospray ionization mode by multiple reaction monitoring (m/z 428.84→198.92 and472.90→434.93 for BOC26P and DSP, respectively). The quantification of BOC26P in rat plasma was fully verified.Results The linearity was established in the range of 50 to 2000 ng/mL(r2≥0.99). The recovery of BOC26P fromspiked plasma were ranged from 96.7% to 110.5%. This method showed acceptable accuracy (3.7% to 6.3%) andprecision (1.5% to 3.1%) both of intra- and inter-day.Conclusion The developed method was successfully applied for three intravenous dose (2, 5, 12.5 mg/kg BOC26P)pharmacokinetics in male and female ratsen_US
dc.identifier.affiliationsInternational Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, Chinaen_US
dc.identifier.affiliationsShenzhen Key Laboratory for Molecular Biology of Neural Development, Guangdong Key Laboratory of Nanomedicine, Institute of Biomedicine and Biotechnology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, 1068 Xueyuan Boulevard, University Town of Shenzhen, Xili Nanshan, Shenzhen 518055, Chinaen_US
dc.identifier.citationLin Lina, Chen Lexing, Xu Jun, Cai Shaohui, Lu Danyi. Developing an UPLC-MSMS Method to Quantify a Novel Anticancer Chalcone BOC26P for Its Pharmacokinetic Study In vivo. Journal of Pharmaceutical and Biomedical Sciences. 2019 Aug; 9(8): 80-92en_US
dc.identifier.issn2230-7885
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/215728
dc.languageenen_US
dc.publisherLawarence Press Pvt. Ltd.en_US
dc.relation.issuenumber8en_US
dc.relation.volume9en_US
dc.source.urihttps://lawarencepress.com/ojs/index.php/JPBMS/article/view/592/pdf_283en_US
dc.subjectBOC26Pen_US
dc.subjectpharmacokineticsen_US
dc.subjectliquid chromatographyen_US
dc.subjecttandem mass spectrometryen_US
dc.titleDeveloping an UPLC-MSMS Method to Quantify a Novel Anticancer Chalcone BOC26P for Its Pharmacokinetic Study In vivoen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jpbms2019v9n8p80.pdf
Size:
1.44 MB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmaceutical and Biomedical Sciences